Abstract:Background: ApoA5, the newest member of the apolipoprotein family, is expressed exclusively in the liver.Although plasma ApoA5 concentrations in humans are very low (114-258 ng/mL) and ~1,000-fold lower than those of ApoB100 on a molar basis, human and mouse studies have clearly shown a key role of ApoA5 in plasma triglyceride (TG) homeostasis.Because ~20% of ApoA5 is secreted into the circulation and its concentration is 7-fold higher in the liver than in plasma, we hypothesize that ApoA5 plays a critical role in regulating hepatic TG metabolism and ApoA5 deficiency profoundly perturbs the balance of daily input and output of fatty acids (FA) in the liver.Methods: Male ApoA5 KO and WT mice were fed a chow diet for 12 mo.Liver pathology was examined by H&E and Sirius Red staining.Lipid droplets (LD) and endoplasmic reticulum (ER) and Golgi fractions were isolated from homogenized liver by ultracentrifugation.Gene expression and protein content were studied by qRT-PCR and Western blots.Lipidomic analysis of liver was performed by ESI-MS/MS.Results: During the 12-mo period, on chow, ApoA5 deficiency significantly reduced TG disposal by inhibiting FA β-oxidation through repressing carnitine palmitoyltransferase-1, coupled with reduced energy expenditure.In WT mice, because it is a LD-associated protein, ApoA5 guided TG-rich LD to the ER for VLDL assembly and subsequently to the Golgi apparatus for hepatic VLDL secretion through its interaction with Plin2, Cideb and ApoB100.ApoA5 deficiency reduces hepatic VLDL secretion by impairing its lipidation and maturation.As a result, accumulation of excess TG within the cytoplasm of hepatocytes induced the formation of numerous large LD, leading to liver steatosis.ApoA5 deficiency significantly increased de novo synthesis of ceramides, the major FA metabolites, by enhancing hepatic serine palmitoyltransferase activity.Due to their hepatocellular lipotoxicity, increased ceramides induced hepatic lipoapoptosis through TNFα by stimulating both caspase-induced apoptosis and ROS-mediated mitochondrial dysfunction in ApoA5 KO, but not WT mice.These alterations triggered NASH with a main histological feature of hepatocellular ballooning in ApoA5 KO mice.Ceramide-induced hepatocyte apoptosis and activation of hepatic stellate cells promoted fibrogenesis by triggering a profibrogenic gene program, leading to liver fibrosis.Conclusions: ApoA5 deficiency in chow-fed mice over a long period leads to spontaneous development of NAFLD, gradually evolving from simple steatosis to NASH, and subsequently to liver fibrosis, which closely recapitulates many aspects of the pathogenic process of NAFLD in patients.These innovative studies will help us understand the mechanisms underlying the critical role of ApoA5 in the pathogenesis of NAFLD and provide novel targets to combat NAFLD by pharmacological intervention.

Targeting ApoC3 Paradoxically Aggravates Atherosclerosis in Hamsters With Severe Refractory Hypercholesterolemia

In Vivo AAV-CRISPR/Cas9–Mediated Gene Editing Ameliorates Atherosclerosis in Familial Hypercholesterolemia

CRISPR/Cas9-mediated knockout of APOC3 stabilizes plasma lipids and inhibits atherosclerosis in rabbits

Apolipoprotein CIII Deficiency Protects Against Atherosclerosis in Knockout Rabbits

Depleting LCAT aggravates atherosclerosis in LDLR-deficient hamster with reduced LDL-Cholesterol level

ApoF Knockdown Increases Cholesteryl Ester Transfer to LDL and Impairs Cholesterol Clearance in Fat-Fed Hamsters.

ApoC2 Deficiency Elicits Severe Hypertriglyceridemia and Spontaneous Atherosclerosis: A Rodent Model Rescued from Neonatal Death.

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors

Abstract 13320: APOO Knockout Elevates Plasma Cholesterol Levels Independent of LDLR and Accelerates Atherosclerosis in Mice

Aggravated Restenosis and Atherogenesis in ApoCIII Transgenic Mice but Lack of Protection in ApoCIII Knockouts: the Effect of Authentic Triglyceride-Rich Lipoproteins with and Without ApoCIII.

Heterozygous Ldlr-Deficient Hamster As A Model To Evaluate The Efficacy Of Pcsk9 Antibody In Hyperlipidemia And Atherosclerosis

A Novel Mouse Model of Familial Combined Hyperlipidemia and Atherosclerosis.

[The Role of Apolipoprotein C3 in the Regulation of Nonalcoholic Fatty Liver Disease, Glucose and Lipid Metabolism, and Islet Β Cell Function].

Dietary-Induced Elevations of Triglyceride-Rich Lipoproteins Promote Atherosclerosis in the Low-Density Lipoprotein Receptor Knockout Syrian Golden Hamster

Advances in Dyslipidaemia Treatments: Focusing on ApoC3 and ANGPTL3 Inhibitors

Idol Depletion Protects against Spontaneous Atherosclerosis in a Hamster Model of Familial Hypercholesterolemia

Hypertriglyceridemia and Delayed Clearance of Fat Load in Transgenic Rabbits Expressing Human Apolipoprotein CIII

41 Cholesterol 7Α-Hydroxylase (CYP7A1) Mediates Resistance to High-Fat Diet-Induced Obesity and Diabetes Through Elevated Tauro-β-Muricholic Acid and Inhibition of Farnesoid X Receptor Signaling in the Intestine

Time-Restricted Feeding Reduces Atherosclerosis in LDLR KO Mice but Not in ApoE Knockout Mice

Untargeted Lipidomic Profiling Reveals Lysophosphatidylcholine and Ceramide as Atherosclerotic Risk Factors in apolipoprotein E Knockout Mice

Targeting angiopoietin-like 3 in atherosclerosis: From bench to bedside